Asuragen, MIND Institute Show Potential of Methylation PCR for Fragile X Testing
June 30, 2011
Asuragen, MIND Institute Show Potential of Methylation PCR for Fragile X Testing
Asuragen said that that in the second half of this year it will release research-use-only reagents for evaluating FMR1 methylation status in the hopes of obtaining independent validation of the technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Asuragen Presents Data Backing New Molecular Test as Better Predictor of Fragile X Risk in Offspring
March 21, 2013 / PCR Insider - Asuragen Using NICHHD Grant to Adapt Fragile X MDx Assay for Newborn Screening
October 6, 2011 / PCR Insider - Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News
March 24, 2011 / PCR Insider - IP Watch: Canon, Esoterix, Life Tech, Asuragen, Rubicon, Roche, and Genereach Win US Patents
April 3, 2013 / PCR Insider - Dx Focus: Quidel RSV/hMPV Test Gets 510(k); Labceutics, Asuragen Partner on BCR-ABL1 Standardization
March 14, 2013 / PCR Insider